NeuroOne Announces CFO Succession Plan as Ron McClurg Retires, Chris Volker Takes Over
NeuroOne Medical Technologies Corporation announced that CFO Ron McClurg will retire effective June 30, 2026, with current COO Chris Volker assuming the permanent CFO role, ensuring a smooth transition as the company advances its growth strategy.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced that Chief Financial Officer Ron McClurg will retire effective June 30, 2026, and will remain as a Senior Advisor through December 31, 2026, to support a smooth transition. Chris Volker, the company's current Chief Operating Officer, will assume the permanent role of CFO, while newly appointed Chief Business Officer David Wambeke will take on many of Volker's previous responsibilities.
The leadership change comes as NeuroOne, a medical technology company focused on surgical solutions for neurological disorders, continues to advance its product pipeline and commercialization efforts. Volker brings over 25 years of operational and financial leadership experience, including senior roles at Abbott, Cardiovascular Systems, Inc. (CSI), and St. Jude Medical. He holds the Chartered Financial Analyst (CFA) designation and an MBA from The Wharton School of the University of Pennsylvania.
Dave Rosa, CEO of NeuroOne, expressed gratitude for McClurg's contributions and confidence in Volker's ability to lead the company's financial strategy. "Chris brings deep leadership experience across medtech, finance, strategy and commercial operations, and I believe he is the right person to step into this role as we continue advancing NeuroOne's technologies and growth strategy," Rosa said in a statement.
McClurg, who served as CFO for over five years, noted that the timing was right for his retirement. "I am proud of this team and the benefits our products are providing for patients," he said, adding that he remains committed to supporting the transition.
Volker expressed honor in taking on the CFO role and highlighted the company's momentum. "NeuroOne has built strong momentum, both in advancing our product pipeline and commercially, and I look forward to working closely with the team," he said.
NeuroOne markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. More information is available at nmtc1.com.
The succession plan underscores NeuroOne's focus on maintaining financial stability and operational continuity as it expands its product offerings and market presence. With Volker's extensive experience in both finance and commercial operations, the company is positioned to navigate its next phase of growth effectively.